Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Current status of allogeneic bone marrow transplantation. Clin Transpl 1990:41-52 PMID: 2103163

Pubmed ID

2103163

Abstract

Use of allogeneic BMTs continues to increase. During the 33-year period between 1955 and 1987, more than 20,000 patients received allogeneic BMTs; more than 50% of these were performed in the 3 years, 1985 through 1987. Transplants are effective therapy for leukemia and other hematologic diseases. They are the treatment of choice for aplastic anemia and chronic myelogenous leukemia, those who fail conventional therapy for acute leukemia, and a variety of immune deficiency disorders. Successful application of BMT is limited by complications such as graft failure, GvHD and interstitial pneumonia, and, until recently, the requirement for an HLA-identical sibling donor. In the past few years, an increasing number of transplants was performed using HLA partially matched related or unrelated donors, with some success. The development of posttransplant complications can often be predicted by risk factor assessment. In this report, current data from the IBMTR are summarized and several risk factors affecting outcome identified.

Author List

Horowitz MM, Bortin MM

Author

Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-0025620167   11 Citations

MESH terms used to index this publication - Major topics in bold

Anemia, Aplastic
Bone Marrow Transplantation
Follow-Up Studies
Graft vs Host Disease
Histocompatibility Testing
Humans
Leukemia
Tissue Donors
Transplantation, Homologous
jenkins-FCD Prod-331 a335b1a6d1e9c32173c9534e6f6ff51494143916